Table 1.
Characteristics of study subjects
| Sample sources | BRCA1 | BRCA2 | BRCA1 and BRCA2a | ||
| n | (% of total) | n | (% of total) | n | |
| EMBRACE | 247 | (64) | 92 | (42) | 0 |
| kConFaB | 96 | (25) | 84 | (38) | 0 |
| AJBCS | 19 | (5) | 22 | (10) | 0 |
| ABCFS | 20 | (5) | 23 | (10) | 1 |
| Total | 382 | 221 | 1 | ||
| Affected breast cancerb | 205 | (54) | 125 | (57) | 1 |
| Affected ovarian cancerb | 24 | (6) | 8 | (4) | 0 |
| Number of families | 257 | 118 | 1 | ||
Questionnaire information on potential confounders was available for 344 BRCA1 carriers (239 EMBRACE, 80 kConFaB, 10 AJBCS and 15 ABCFS) and 200 BRCA2 carriers (92 EMBRACE, 76 kConFaB, 12 AJBCS, and 20 ABCFS). aOne individual was found to carry a deleterious mutation in both BRCA1 and BRCA2 [19]. bCancer type refers to first primary cancer diagnosis. One BRCA2 carrier with breast cancer was censored as unaffected at age of prior mastectomy. ABCFS, Australian Breast Cancer Family Study; AJBCS, Australian Jewish Breast Cancer study; EMBRACE, Evaluation of Mutant BRCA Carrier Epidemiology study; kConFaB, Kathleen Cuningham Consortium for Research into Familial Breast Cancer.